250 results about "Ige reactivity" patented technology

The discovery and application of immune checkpoint inhibitors (ICI) have significantly promoted cancer treatment. However, the response rate is still low in gastrointestinal (GI) cancers. To explore novel adjuvant treatment options, we performed fecal microbiota transplantation (FMT) of healthy donors on 10 GI cancer patients with resistance to anti-PD-(L) 1 treatment. The combination of FMT and anti-PD1 treatment was well tolerated and no serious adverse reaction was observed. Two out of 10 patients restored clinical responsiveness to anti-PD1 after FMT. Clinical benefits were shown to be associated with better colonization of co-occurred immunogenic microbes from donors, alongside activated immune status reflected by the peripheral immune cell population. Moreover, we identified microbial signatures of ICI responsiveness and validated in an independent cohort. Our study demonstrates the feasibility of FMT as a potential adjuvant therapy for ICI irresponsive GI cancer patients and laid a foundation for LBP / consortia development to enhance ICI efficacy.

The invention discloses a preparation method and application of a self-reactive animal model. An autoreactive animal model is constructed based on an SWHEL system, it is found through the model that MTCH2 is a key target for regulating and controlling B cell autoreactivity, deletion of MTCH2 will cause generation of a large number of autoreactive B cells subjected to antibody category conversion, the disease risk is increased, and a basis is provided for research of B cell autoreactivity related mechanisms.

The present disclosure provides systems and methods for detecting anti-NMDAR autoantibodies based on the strong affinity of the anti-NMDAR autoantibodies to a plurality of non-random anti-NR1s coupled to a solid support. The present disclosure also provides methods of treatment for anti-NMDAR pathology by the therapeutic anti-NMDAR antibody ART5803. The present disclosure also provides methods and systems for screening and predicting potential responsiveness to ART5803 therapy.

The present invention relates to a new thiol-reactive coupling moiety as shown in formula (I), a linker containing the coupling moiety, a linker-payload conjugate, an antibody-drug conjugate based on the linker and the use thereof, and further relates to a pharmaceutical composition containing the antibody-drug conjugate, and the use of the antibody-drug conjugate for treating and / or preventing a disease.

The present invention relates to an antibody specific for Staphylococcus aureus protein A, and to a composition or kit comprising same for detecting Staphylococcus aureus or diagnosing skin conditions. The monoclonal antibody according to the present invention is highly reactive to antigens, and, particularly, can detect antigens rapidly and accurately even at low concentrations due to two antibodies of different CDRs having been combined and used as capture and detection antibodies, thus allowing the monoclonal antibody to be used in rapid self-diagnostic kits and the like. In using the monoclonal antibody, the degree of proliferation of Staphylococcus aureus on the skin surface and the like can be visually checked, abnormal states of the skin, such as inflammation and excessive immune response, can be diagnosed, incidence probability and persistence of related diseases can be predicted, and subsequent treatment methods can be determined.

The invention provides antibody conjugate compositions of Formula I comprising an antibody linked by conjugation to one or more target protein binder and VHL ligand (TPI-VHL) moieties. The invention also provides TPI-VHL derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the antibody conjugates through a linker or linking moiety. The invention further provides methods of treating diseases and disorders such as cancer with the antibody conjugates.

A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and / or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.

Systems and methods for determining the likely responsiveness of a human cancer subject to a checkpoint blockade immunotherapy regimen are provided. Sequencing reads are obtained from samples from the subject representative of the cancer. A human leukocyte antigen type and a plurality of clones is determined from the sequencing reads. For each clone, an initial frequency Xα in the one or more samples is determined and a corresponding clone fitness score of the clone is computed, thereby computing clone fitness scores. Each such fitness score is computed by identifying neoantigens in the respective clone, computing a recognition potential for each neoantigen, and determining the corresponding clone fitness score of the respective clone as an aggregate of these recognition potentials. A total fitness, quantifying the likely responsiveness of the subject to the regimen, is computed by summing the clone fitness scores across the plurality of clones.

The invention provides a single-domain antibody capable of specifically recognizing GPRC5D, which has relatively strong binding activity and reaction specificity, also has good species cross reactivity, is of great significance to research and development in different species models, and is beneficial to acceleration of a transformation process from a laboratory to clinic. The antibody sequences A12 and C07 provided by the invention can be used for constructing chimeric antigen receptor T cells, and the chimeric antigen receptor T cells can be used for treating multiple myeloma.

The invention belongs to the technical field of immunological detection, and particularly relates to an antibody for resisting porcine pseudorabies virus glycoprotein gB and application of the antibody. The antibody is a first antibody or a second antibody, amino acid sequences of light chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.3-5, and amino acid sequences of heavy chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.8-10; the amino acid sequences of light chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.13-15, and the amino acid sequences of heavy chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.18-20. The antibody and the PRV glycoprotein gB have good reactivity, recognition specificity and binding sensitivity, the detection sensitivity and accuracy of the gB protein or the anti-gB protein antibody are improved, and an antibody tool with excellent performance is provided for qualitatively or quantitatively evaluating the immune effect of swine herd vaccines and detecting the content of porcine pseudorabies virus antigens in a sample.

The invention provides a specific binding polypeptide of a targeted cell membrane receptor Fc epsilon RI alpha and application of the specific binding polypeptide. The amino acid sequence of the polypeptide is shown in any one of (I) SEQ ID NO: 1-6; (II) an amino acid sequence with at least 90% identity as shown in any one of SEQ ID NO: 1-6, and is specifically combined with a cell membrane receptor Fc epsilon RI alpha. Experimental results show that the Fc [epsilon] RI [alpha] specific binding polypeptide can inhibit IgE-mediated mast cell dependent anaphylaxis to a certain extent, which prompts that the Fc [epsilon] RI [alpha] specific binding polypeptide has a certain inhibition effect on IgE-mediated I-type anaphylaxis, and lays a foundation for further research and development of novel biological targeting drugs for treating allergic diseases.

The present invention relates to a medicament for treatment and / or prevention of cancer, comprising an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein, and a MAPK pathway inhibitor together or separately in combination.

The disclosure provides the development of enantiomer-specific 7V-arylpyrazole dipeptides as novel N0D2 agonists which are effective at promoting immune checkpoint inhibitor therapy requiring N0D2 for activity. Given the significant functions of N0D2 in innate and adaptive immunity, these novel agonists afford new therapeutic compounds for a variety of NOD2-responsive diseases.

The invention belongs to the field of biology, and discloses an mRNA (messenger ribonucleic acid) with a nucleotide sequence as shown in SEQ ID NO.3. Antiserum of a strain (A / chick / Gansuu / 28 / 2024) corresponding to the mRNA has relatively good reactivity with other strains and poorer reaction with a current vaccine strain RE-13, the branched strain is a current epidemic strain, and the mRNA prepared from the HA gene of the strain has the advantage of strong protection; the invention also aims to provide the mRNA, application thereof and a vaccine.

Provided in the present invention are an anti-TLR7 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition thereof. The antibody or the antigen-binding fragment thereof can specifically bind to a human or simian TLR7 antigen and does not bind to murine TLR7, exhibits significant TLR7 antigen-binding activity, and can effectively inhibit various inflammatory cytokines produced upon TLR7 activation. The anti-TLR7 antibody or the antigen-binding fragment thereof can be used, either as a monotherapy or in combination with other drugs, for treating and / or preventing diseases pathologically associated with the TLR7 target, including immune inflammation-related diseases, allergic diseases, infectious diseases, cancers, etc.

The invention concerns homogenous antibody-conjugates with high payload loading (high DAR) obtained by site-specific conjugation to a single antibody N-glycan. The conjugates according to the invention are homogeneous, i.e. have a DAR at or close to the theoretical DAR with a narrow distribution, and do not require any genetic modification of the antibody. The invention further concerns a modular, non-genetic preparation method for such conjugates, involving three simple steps and starting from any antibody. These steps are (a) enzymatic remodeling of the glycan to give an antibody functionalized with two or four click probes per antibody, (b) strain-promoted cycloaddition with a multivalent, bifunctional reagent comprising one cyclic alkyne and at least two click probes that are not reactive towards the cyclic alkyne, and (c) inverse electron-demand Diels-Alder cycloaddition of the click probes with branched linker-drug constructs comprising one cyclic alkyne or strained alkene, connected to one or more payloads preferably connected through a cleavable linker. The resulting conjugates, with DAR6 or higher, are rapidly generated with high homogeneity and with surprising stability. In addition, HIC profiles of the resulting ADCs indicate small relative retention time and therefore show high potential in the targeting of tumour cells and / or the treatment of cancer.

The invention belongs to the field of biology, and relates to a broad-spectrum monoclonal antibody aiming at avian influenza virus M1 protein and application of the broad-spectrum monoclonal antibody, the monoclonal antibody has specific reaction with A549 cells infected by avian influenza, has no specific reaction with Newcastle disease virus, duck tembusu virus, goose astrovirus and infectious laryngitis virus, has good specificity, and can be used for preparing the broad-spectrum monoclonal antibody. The 5G9 monoclonal antibody has good reactivity with A549 cells infected by H1-H11 subtype AIV, has good broad spectrum, can be used for detecting M1 protein sub-localization after the AIV infected cells are detected by using the 5G9 monoclonal antibody, and can be used for indicating the infection process of the AIV.

The invention provides an anti-TLR7 antibody or an antigen binding fragment and a pharmaceutical composition thereof, the antibody or the antigen binding fragment thereof can be specifically bound with a human or monkey TLR7 antigen and is not bound with mouse TLR7, has remarkable TLR7 antigen binding activity, and can effectively inhibit various inflammatory cytokines generated by TLR7 activation. The anti-TLR7 antibody or the antigen binding fragment thereof can be used as a single agent or a drug combination and can be used for treating and / or preventing diseases related to TLR7 target pathology, including immune inflammation related diseases, allergic diseases, infectious diseases or cancers and the like.

The invention relates to the field of analyzing cells and cell division, in particular to means and methods for detecting low numbers of dividing immune cells in blood samples. Provided is an in vitro method for detecting proliferating cells, comprising the steps of: (i) culturing cells in the presence of a nucleoside analog comprising a first reactive unsaturated group to allow for incorporation of the nucleoside analog in the DNA of the cells; (ii) concentrating the nucleoside-labeled cells by covalent immobilization to a solid surface comprising a coating of (3-aminopropyl)triethoxysilane (APTES) or branched polyethyleneimine (PEI) that is activated by glutaraldehyde (GA); (iii) optionally fixing the concentrated and covalently immobilized cells with formaldehyde; (iv) contacting the covalently immobilized cells with a detection probe comprising a second reactive unsaturated group, such that a [3+2] or [4+2] cycloaddition occurs between the first and second reactive unsaturated groups; and (v) determining the amount of detection probe attached to the DNA of the immobilized cells to measure cellular proliferation.

The present invention relates to a biomarker for predicting immunotherapeutic responsiveness based on spatial transcriptome analysis and uses thereof and, in particular, to: a marker composition for predicting the responsiveness of cancer patients to immunotherapy; a composition for predicting the responsiveness of cancer patients to immunotherapy; a kit for predicting the responsiveness of cancer patients to immunotherapy, comprising the composition; a method for providing information for predicting the responsiveness of cancer patients to immunotherapy; and a method for providing information for predicting the survival prognosis of cancer patients. The biomarker for predicting immunotherapeutic responsiveness, according to the present invention, was discovered by applying spatial transcriptome technology and analyzing cell group-specific gene expression values according to location information of cells in tissue sections, and can more precisely and accurately predict the responsiveness of cancer patients to immunotherapy and the survival prognosis of patients, thus enabling suitable treatments for patient groups, which may result in improved therapeutic effects and a reduction in pain and costs for patients.

An assay for autologous primary immune cells is described, in which individual blood cells can be functionally screened simultaneously for individual antigens of interest, such as T-cell epitopes, without the need for HLA haplotype-specific reagents. An oligonucleotide-labeled hash-tracking system, followed by deconvolution via single-cell sequencing, correlates antigen reactivity with individual T cells.

Some embodiments of the present application provide a compound comprising Fc binding unit. The compound comprising Fc binding unit of the present application may be used to transfer a group of interest to an antibody in a position-specific manner. Furthermore, some embodiments of the present application provide a method for preparing an antibody conjugate comprising a group of interest (for example, a reactive group) using the compound comprising Fc binding unit.

The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more toll-like receptor (TLR), amino-azepine derivatives. The invention also provides TLR agonist amino-azepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

Disclosed are methods of predicting a. subject's responsiveness to an immunotherapy comprising detecting the presence and / or amount of a miR155 gene signature in the subject or a sample from the subject, wherein the miR155 gene signature comprises one or more of miR155, CD3E, CD3G, CD8A, CD8B, CXCR6, FXYD5, GZMB, ID2, IFNgamma, LAGS, NKG7, PDCD1, S100A4, and TIGIT; and comparing the presence and / or amount of the miR155 gene signature to a control sample or threshold, wherein the presence and / or an altered amount of the miR155 gene signature relative to the presence or amount in the control sample or threshold indicates the subject will be responsive or is responding to the immunotherapy.

The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more toll-like receptor (TLR), amino-azepine derivatives. The invention also provides TLR agonist amino-azepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

A method for measuring an oligonucleotide which is simpler and more sensitive and has excellent specificity and quantitative capability compared to the conventional measurement method is provided. Moreover, a method for measuring an oligonucleotide having excellent specificity which can distinguish the intact target oligonucleotide (unchanged form) and a metabolite thereof and detect the unchanged form only is provided. In a hybridization method using a capture probe and an assist probe, by inserting a spacer between a solid phase and a nucleic acid probe contained in the capture probe, it becomes possible not only to detect the target oligonucleotide in a sample but also to distinguish from a metabolite of a nucleic acid drug.

Providing cancer prediction technology [Solution] This disclosure provides a method for predicting the effectiveness of a cancer vaccine, which includes confirming the reactivity of immune cells (e.g., peripheral blood mononuclear cells) derived from the patient to stimulation by a cancer antigen corresponding to the cancer vaccine or the antigenic portion of the cancer antigen, and predicting and calculating the effectiveness of the cancer vaccine (e.g., response (response and duration) / determining which patients should receive the vaccine) based on the reactivity.

The present invention provides antibody compounds that contain a substitution of cysteine for the reactive lysine residue (lysine 93 by Kabat numbering) in the hydrophobic cleft (38C2_Cys). The invention also provides antibody drug conjugate compounds (ADCs) that contain cargo moieties that are site-specifically conjugated to the engineered cysteine residue in the 38C2_Cys variant antibody. Further provided in the invention are therapeutic applications of the compounds.

The invention provides a fish creatine kinase sensitization and immune cross reactivity analysis method which comprises the following steps: preparing a fish muscle water-soluble protein crude extract, separating 40-45kDa protein components in the fish muscle crude extract through SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), and screening a target sensitization protein combined with IgE / IgG through immunoblotting; the method comprises the following steps: extracting total RNA of grass carp and synthesizing cDNA, designing a creatine kinase specific primer for amplification to obtain a creatine kinase gene sequence, and carrying out bioinformatics analysis after sequencing verification; the method comprises the following steps: cloning a creatine kinase gene to an expression vector, transforming escherichia coli BL21, performing IPTG induced expression, and performing urea gradient dialysis renaturation on an inclusion body to obtain the recombinant grass carp creatine kinase. Detecting the IgE binding activity of the recombinant grass carp creatine kinase and the serum of the allergic patient through dot hybridization; the IgG cross reactivity of the recombinant grass carp creatine kinase and the blue crab arginine kinase is verified through indirect ELISA; the IgE cross reaction degree of the recombined grass carp creatine kinase and the blue crab arginine kinase is quantified through inhibitory dot hybridization.

A method for measuring kinetics of Ca2+ flux in differentially responding T cells that form monolayer on the glass surface in response to antigenic peptides or live target cells comprising: immobilizing T cells labeled with Ca2+ sensitive fluorophore on the glass bottom of a well, covered with capturing antibody or a capturing protein that bind to non-stimulatory T-cell surface receptor; adding to the well a single or multiple peptide epitopes that binds to the cell surface MHC molecules to be presented for recognition by cognate T cells; the stimulatory signal could also be delivered by live target cells that display peptide epitope(s); wherein the recognition of stimulatory of pMHC by the peptide specific T cells leads to increase of intracellular Ca2+ level and fluorescence intensity in the responding T cells, which is then identified after the subtracting fluorescence intensity for every T cell before and after the addition of the peptide antigens; scoring each responding T cell into a category according to three categories including: a rapid and sustained T-cell response, an oscillatory response, or a delayed and oscillatory response; and measuring changes in number of an individual T cells with increased intracellular fluorescence as function of time provides the kinetic curve of the TCR-mediated Ca2+ signaling.